Discovery of nitroaryl urea derivatives with antiproliferative properties

References

• WHO. 2014. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx [last accessed Nov 2014]
   Google Scholar
• Cohen P. Protein kinases – the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309–15
   PubMed Web of Science ®Google Scholar
• Melnikova I, Golden J. Targeting protein kinases. Nat Rev Drug Discov 2004;3:993–4
   PubMed Web of Science ®Google Scholar
• Adams JA. Kinetic and catalytic mechanisms of protein kinases. Chem Rev 2001;101:2271–90
   PubMed Web of Science ®Google Scholar
• Giamas G, Stebbing J, Vorgias CE, Knippschild U. Protein kinases as targets for cancer treatment. Pharmacogenomics 2007;8:1005–16
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–37
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nat Med 1996;2:561–6
   PubMed Web of Science ®Google Scholar
• Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911–14
   PubMed Web of Science ®Google Scholar
• Das J, Chen P, Norris D, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure–activity relationship studies toward the discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006;49:6819–32
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994;79:573–82
   PubMed Web of Science ®Google Scholar
• Krystof V, Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 2010;11:291–302
   PubMed Web of Science ®Google Scholar
• Malumbres M. Cyclin-dependent kinases. Genome Biol 2014;15:122
   PubMed Web of Science ®Google Scholar
• Malumbres M, Harlow E, Hunt T, et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009;11:1275–6
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Milestones in cell division: to cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222–31
   PubMed Web of Science ®Google Scholar
• Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011;137:1409–18
   PubMed Web of Science ®Google Scholar
• Blachly JS, Byrd JC. Emerging drug profile: cyclin-dependent kinase inhibitors. Leukemia Lymphoma 2013;54:2133–43
   PubMed Web of Science ®Google Scholar
• Havlíček L, Hanuš J, Veselý J, et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 1997;40:408–12
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Therap 2004;3:1427–38
   PubMed Web of Science ®Google Scholar
• Montagnoli A, Valsasina B, Croci V, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 2008;4:357–65
   PubMed Web of Science ®Google Scholar
• Schonbrunn E, Betzi S, Alam R, et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J Med Chem 2013;56:3768–82
   PubMed Web of Science ®Google Scholar
• Honma T, Hayashi K, Aoyama T, et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem 2001;44:4615–27
   PubMed Web of Science ®Google Scholar
• Pedersen DS, Rosenbohm C. Dry column vacuum chromatography. Synthesis 2001;16:2431–4
   Google Scholar
• Allali M, Benoist E, Habbadi N, et al. Design and synthesis of new ethylenediamine or propylenediamine diacetic acid derivatives for Re(I) organometallic chemistry. Tetrahedron 2004;60:1167–74
   Web of Science ®Google Scholar
• Bremer O. Über die Synthese nitrierter 2,3-dihydro-pyrimidazole. Justus Liebigs Annalen der Chemie 1936;521:286–97
   Google Scholar
• Rzeski W, Paduch R, Klatka J, et al. Establishment and preliminary characterization of two cell lines derived from larynx carcinoma. Folia Histochem Cytobiol 2002;40:195–6
   PubMed Web of Science ®Google Scholar
• SADABS. 2004/1 ed. Madison (WI): Bruker AXS Inc.; 2005
   Google Scholar
• Sheldrick G. A short history of SHELX. Acta Crystallogr Sect A 2008;64:112–22
   PubMed Web of Science ®Google Scholar
• Farrugia L. WinGX and ORTEP for Windows: an update. J Appl Crystallogr 2012;45:849–54
   Web of Science ®Google Scholar
• LigPrep. Schrödinger. 2.4 ed. New York: LLC; 2010
   Google Scholar
• Epik. Schrödinger. 2.1 ed. New York: LLC; 2010
   Google Scholar
• Becke AD. Density–functional thermochemistry. III: the role of exact exchange. J Chem Phys 1993;98:5648–52
   Web of Science ®Google Scholar
• Lee C, Yang W, Parr R. Development of the Colle–Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B 1988;37:785–9
   PubMed Web of Science ®Google Scholar
• Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 09. Wallingford (CT): Gaussian, Inc.; 2009
   Google Scholar
• Pedretti A, Villa L, Vistoli G. VEGA – an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming. J Comput-Aided Mol Des 2004;18:167–73
   PubMed Web of Science ®Google Scholar
• Discovery Studio. 3.5 ed: Biovia. Available from: http://accelrys.com/products/discovery-studio/ [last accessed Nov 2014]
   Google Scholar
• ACDLabs. Available from: http://www.acdlabs.com/ [last accessed Nov 2014]
   Google Scholar
• Bowers KJ, Chow E, Xu H, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the 2006 ACM/IEEE conference on Supercomputing. Tampa (FL): ACM; 2006. p. 84
   Google Scholar
• ArgusLab. Available from: http://www.arguslab.com/arguslab.com/ArgusLab.html [last accessed Nov 2014]
   Google Scholar
• The PyMOL Molecular Graphics System. Schrödinger. 0.99 ed: LLC. Available from: https://www.pymol.org/pymol [last accessed Nov 2014]
   Google Scholar
• Duspara PA, Islam MS, Lough AJ, Batey RA. Synthesis and reactivity of N-alkyl carbamoylimidazoles: development of N-methyl carbamoylimidazole as a methyl isocyanate equivalent. J Org Chem 2012;77:10362–8
   PubMed Web of Science ®Google Scholar
• Dobrowolski MA, Cyrański MK, Pisklak M, Wawer I, Matosiuk D. Structural studies of 1-aryl-2-aminoimidazolinium bromides: focus on tautomer preference of the 2-aminoimidazoline moiety in the solid state. Pol J Chem 2007;81:1037–48
   Google Scholar
• Allen FH, Kennard O, Watson DG, et al. Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds. J Chem Soc Perkin Trans 2 1987;12:S1–19
   Google Scholar
• Wysocki W, Matosiuk D, Karczmarzyk Z, et al. 1-(3-Chlorophenyl)-3-(1-p-tolylimidazolidin-2-ylidene)urea. Acta Crystallogr Sect E 2009;65:o40
   Web of Science ®Google Scholar
• Wang GT, Li G, Mantei RA, et al. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyano-pyrazi-2-yl)ureas as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. J Med Chem 2005;48:3118–21
   PubMed Web of Science ®Google Scholar
• Mitchell SA, Danca MD, Blomgren PA, et al. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4. Bioorg Med Chem Lett 2009;19:6991–5
   PubMed Web of Science ®Google Scholar
• Chen Z, Venkatesan AM, Dos Santos O, et al. Stereoselective synthesis of an active metabolite of the potent PI3 kinase inhibitor PKI-179. J Org Chem 2010;75:1643–51
   PubMed Web of Science ®Google Scholar
• Yin Y, Lin L, Ruiz C, et al. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors. J Med Chem 2013;56:3568–81
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Hirte HW. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Design 2002;8:2249–53
   PubMed Web of Science ®Google Scholar
• Yue EW, DiMeo SV, Higley CA, et al. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: heterocycles at C3. Bioorg Med Chem Lett 2004;14:343–6
   PubMed Web of Science ®Google Scholar
• Honma T, Yoshizumi T, Hashimoto N, et al. A novel approach for the development of selective Cdk4 inhibitors: Library design based on locations of Cdk4 specific amino acid residues. J Med Chem 2001;44:4628–40
   PubMed Web of Science ®Google Scholar
• Vermeulen K, Strnad M, Kryštof V, et al. Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases. Leukemia 2002;16:299–305
   PubMed Web of Science ®Google Scholar
• Gray NS, Wodicka L, Thunnissen A-MWH, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998;281:533–8
   PubMed Web of Science ®Google Scholar
• Wang S, Meades C, Wood G, et al. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem 2004;47:1662–75
   PubMed Web of Science ®Google Scholar
• Chu X-J, DePinto W, Bartkovitz D, et al. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J Med Chem 2006;49:6549–60
   PubMed Web of Science ®Google Scholar
• Kryštof V, Cankař P, Fryšová I, et al. 4-Arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 2006;49:6500–9
   PubMed Web of Science ®Google Scholar